Navigation Links
Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial

more than 300 papers in peer-reviewed journals.

Dr. Low is Head of the Department of Microbiology at the Toronto Medical Laboratories and Mount Sinai Hospital. He is also Medical Director, Ontario Public Health Laboratories, Ministry of Health and Long-Term Care. He is a Professor at the University of Toronto in the Department of Laboratory Medicine and Pathobiology and Department of Medicine. He is currently Head of the Division of Microbiology in the Department of Laboratory Medicine and Pathobiology.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... 2015 Par Pharmaceutical Companies, Inc. announced today ... August 7, 2015 at 9:00 a.m. EDT to review ... June 30, 2015.  Par is privately held and currently ... its filings with the Securities and Exchange Commission and ... by following the instructions at http://www.parpharm.com/financialinfo .  Par ...
(Date:8/3/2015)... , Aug. 3, 2015   ConvergeHEALTH ... pharmaceutical company Allergan plc is expanding ... and Intermountain Healthcare to include women,s ... ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world clinical ... "We look forward to expanding our ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4
... Calif. and SPRINGFIELD, Va. Oct. 29 Varian Medical Systems, ... Foundation has placed an order for five Varian TrueBeam™ systems ... CURE Foundation, which placed the order in September, plans to ... the U.S. East Coast during 2011.   ...
... Accuray Incorporated (Nasdaq: ARAY ), a global ... Creekside Cancer Care on their use of the CyberKnife ... in the world to install and begin treating patients with ... and clinicians at Creekside Cancer Care quickly reported that average ...
Cached Medicine Technology:CURE Foundation Selects Varian Medical Systems to Supply Radiotherapy Technology for Five New Cancer Centers 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 3CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 4
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and ... chin. Kybella is similar to deoxycholic acid, which occurs naturally in the body and ... options to treat this area of the body. These are invasive procedures and very ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... Decatur, Illinois (PRWEB) , ... August 03, 2015 , ... ... (IBAM NA) effective July 31. , The acquisition includes all of IBAM NA’s ... the opportunity to have both, a robust regionally located business, as well as a ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... announced today that Joe Williams has joined its growing California employee benefits division. ... differentiated service model to his clients. Mr. Williams will be joining the newly ...
(Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health Solutions has promoted ... the company’s Medicare and Federal Employee Programs (FEP) lines of business. , ... for members. In this role, Scott is responsible for overseeing the growth, finance ...
Breaking Medicine News(10 mins):Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
... Highmark Blue Cross Blue Shield,United Concordia Companies, ... healthy smiles and lifestyles for Pittsburghers. Beginning at ... 19, a free clinic will,offer health information and ... For far too long, oral health has ...
... drug offers new hope , , FRIDAY, July 18 (HealthDay News) ... the search for treatments against Alzheimer,s disease. , In one ... The Lancet , an older drug called dimebon significantly improved ... failed to prevent the progression of Alzheimer,s -- even though ...
... 18 minSURG Corporation,producers of the TruFUSE(R) ... of minSURG International, Incorporated. The,international division has ... the TruFUSE procedure and products., CEO, ... Germany,Greece, South Korea, Netherlands, Singapore, Taiwan, Turkey ...
... is showing the benefits of resistance training in keeping older ... a postdoctoral research fellow with UQ and Blue Care, said ... age of 65 responded to resistance training. , "What ... improve muscle strength, power and functional performance." Dr Henwood said. ...
... the earliest events occurring immediately upon infection with HIV-I ... the immune system earlier than was previously understood. According ... the window of opportunity for successful intervention may be ... after transmission, as researchers had previously believed. , Appearing ...
... 2008 -- The legal and ethical issues facing medical ... than some other areas of medicine. Certain activities, such ... federal and state governments. Other activities, such as minimum ... state to state. , A number of distinguished ...
Cached Medicine News:Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:minSURG(TM) Corporation Launches International Division 2Health News:The benefits of a little resistance for older adults 2Health News:HIV conquers immune system faster than previously realized 2Health News:HIV conquers immune system faster than previously realized 3Health News:Legal and ethical issues in medical physics 2Health News:Legal and ethical issues in medical physics 3Health News:Legal and ethical issues in medical physics 4Health News:Legal and ethical issues in medical physics 5Health News:Legal and ethical issues in medical physics 6Health News:Legal and ethical issues in medical physics 7
The Vitatron Excellence SS+ lead series are endocardial silicone leads providing ease of handling and optimal pacing characteristics....
... The Vitatron Impulse II lead series ... designed to extend the longevity of ... efficient pacing. The high impedance of ... the small electrode surface, combined with ...
CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Medicine Products: